Contact
Please use this form to send email to PR contact of this press release:
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
TO:
Please use this form to send email to PR contact of this press release:
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
TO: